Biogen

Yahoo Finance • 10 hours ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbache... Full story

Yahoo Finance • yesterday

Stocks Climb as Technology Shares Rebound

The S&P 500 Index ($SPX) (SPY) today is up by +1.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.58%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +2.01%.  December E-mini S&P futures (ESZ25) are up +1.28%, and December E... Full story

Yahoo Finance • yesterday

Stocks Supported by Strength in Tech and Fed Rate Cut Expectations

The S&P 500 Index ($SPX) (SPY) today is up by +0.61%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +1.51%.  December E-mini S&P futures (ESZ25) are up +0.61%, and December E... Full story

Yahoo Finance • yesterday

Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps

Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies. Continue Reading View Comments... Full story

Yahoo Finance • yesterday

Biogen to gain from Novo Nordisk Alzheimer’s failure, says Jefferies

Investing.com -- Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies. The trials, which tested semaglutide (GLP1) in early Alzheimer’s disease, did not meet the primary... Full story

Yahoo Finance • yesterday

Biogen, Dayra Therapeutics Partner To Develop Oral Macrocyclic Peptides For Immunological Diseases

(RTTNews) - Biogen Inc. (BIIB) said Monday that it has entered into a partnership with Dayra Therapeutics to discover and develop oral macrocyclic peptides for immunological conditions. Under the collaboration, the companies will jointly... Full story

Yahoo Finance • yesterday

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an addi... Full story

Yahoo Finance • 3 days ago

Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1

[Novo Nordisk office in Fremont, California, USA] JHVEPhoto/iStock Editorial via Getty Images Lilly’s (LLY [https://seekingalpha.com/symbol/LLY]) recent climb to reach a $1T market cap will come under scrutiny in the coming days when Novo... Full story

Yahoo Finance • 4 days ago

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fur... Full story

Yahoo Finance • 7 days ago

A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results

Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies.... Full story

Yahoo Finance • 7 days ago

AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images * The U.S. Food and Drug Administration (FDA) on Tuesday announced the approval of Epkinly, a bispecific antibody developed by AbbVi... Full story

Yahoo Finance • 8 days ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –... Full story

Yahoo Finance • 8 days ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development –... Full story

Yahoo Finance • 9 days ago

Sandoz Announces Launch Of TYRUKO In The US

(RTTNews) - Sandoz announced that TYRUKO or natalizumab-sztn is available to patients in the US. Developed by Polpharma Biologics, TYRUKO is the only FDA approved natalizumab biosimilar for the treatment of relapsing forms of multiple scle... Full story

Yahoo Finance • 9 days ago

Notable healthcare headlines for the week: Health insurers, Eli Lilly, Merck in focus

Wall Street saw a mixed week, with the benchmark S&P 500 Index adding a marginal 0.08%, the NASDAQ Composite Index losing 0.45%, and the Dow Jones Industrial Average Index rising 0.34%. However, the S&P 500 Health Care Index Sector (XLV [... Full story

Yahoo Finance • 11 days ago

Biogen Completes Acquisition of Alcyone Therapeutics

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such a... Full story

Yahoo Finance • 12 days ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbache... Full story

Yahoo Finance • 19 days ago

Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: HSBC upgraded Caterpillar (CAT) to Buy... Full story

Yahoo Finance • 19 days ago

Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More

mezzotint / Shutterstock.com Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some of... Full story

Yahoo Finance • 19 days ago

Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift

Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potentia... Full story